About this trial
Cirrhotic cardiomyopathy is associated with increased risk of complications like hepatorenal syndrome, refractory ascites, impaired response to stressors including sepsis, bleeding or transplantation, poor health related quality of life and increased morbidity and mortality. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre.
Eligibility criteria
Qualifiers
Age range of 18-65 years
Cirrhosis with critical illness admitted to the Liver Intensive Care Unit
Disqualifiers
Age >65 years
Chronic renal disease
Pregnancy and peripartum cardiomyopathy
Valvular heart disease
Trial design
Treatments tested in this trial
- Echocardiographic assessment
- Histopathology and Immunohistochemistry
Treatment groups
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.